A detailed history of Legal & General Group PLC transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 18,697 shares of AKBA stock, worth $33,467. This represents 0.0% of its overall portfolio holdings.

Number of Shares
18,697
Previous 18,697 -0.0%
Holding current value
$33,467
Previous $24,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$0.94 - $1.55 $686 - $1,131
730 Added 4.06%
18,697 $24,000
Q2 2024

Aug 14, 2024

BUY
$0.86 - $1.63 $15,451 - $29,286
17,967 New
17,967 $18,000
Q3 2022

Nov 14, 2022

SELL
$0.3 - $0.46 $4,182 - $6,413
-13,943 Closed
0 $0
Q2 2022

Aug 22, 2022

SELL
$0.32 - $0.67 $33,048 - $69,194
-103,276 Reduced 88.11%
13,943 $5,000
Q1 2022

May 16, 2022

BUY
$0.72 - $2.93 $3,806 - $15,490
5,287 Added 4.72%
117,219 $84,000
Q4 2021

Feb 14, 2022

BUY
$2.26 - $3.34 $11,044 - $16,322
4,887 Added 4.57%
111,932 $253,000
Q3 2021

Nov 15, 2021

BUY
$2.35 - $3.88 $69,865 - $115,352
29,730 Added 38.45%
107,045 $308,000
Q2 2021

Aug 12, 2021

BUY
$2.83 - $4.2 $122,009 - $181,074
43,113 Added 126.05%
77,315 $293,000
Q1 2021

May 17, 2021

BUY
$2.92 - $5.06 $75 - $131
26 Added 0.08%
34,202 $116,000
Q4 2020

Feb 12, 2021

SELL
$2.22 - $3.78 $721 - $1,228
-325 Reduced 0.94%
34,176 $96,000
Q3 2020

Nov 13, 2020

SELL
$2.39 - $13.08 $9,593 - $52,503
-4,014 Reduced 10.42%
34,501 $87,000
Q2 2020

Aug 14, 2020

BUY
$6.67 - $13.58 $115,764 - $235,694
17,356 Added 82.03%
38,515 $523,000
Q1 2020

May 14, 2020

SELL
$4.1 - $10.24 $20,057 - $50,094
-4,892 Reduced 18.78%
21,159 $161,000
Q3 2019

Nov 13, 2019

BUY
$3.55 - $5.4 $11,782 - $17,922
3,319 Added 14.6%
26,051 $102,000
Q2 2019

Aug 14, 2019

BUY
$4.1 - $8.05 $24,345 - $47,800
5,938 Added 35.36%
22,732 $110,000
Q4 2018

Feb 15, 2019

BUY
$5.39 - $9.15 $50,013 - $84,902
9,279 Added 123.47%
16,794 $93,000
Q2 2018

Aug 10, 2018

SELL
$9.15 - $11.34 $6,807 - $8,436
-744 Reduced 9.01%
7,515 $75,000
Q1 2018

May 17, 2018

SELL
$9.53 - $15.68 $27,122 - $44,625
-2,846 Reduced 25.63%
8,259 $79,000
Q4 2017

Feb 13, 2018

BUY
$14.24 - $19.59 $158,135 - $217,546
11,105
11,105 $167,000

Others Institutions Holding AKBA

About Akebia Therapeutics, Inc.


  • Ticker AKBA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 183,848,992
  • Market Cap $329M
  • Description
  • Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...
More about AKBA
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.